Latest Janssen Biotech Inc. Stories
Approval represents fourth indication for IMBRUVICA in the U.S. HORSHAM, Pa., Jan. 29, 2015 /PRNewswire/ -- Janssen Biotech, Inc. ("Janssen") today announced that the U.S.
- First and Only FDA-Approved Treatment for WM Patients SUNNYVALE, Calif., Jan. 29, 2015 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S.
SOUTH SAN FRANCISCO, Calif., Jan.
-- Collaboration Combines Isis' RNA-Targeted Technology With Expertise of Janssen in Autoimmune Disorders and Therapeutic Formulation -- CARLSBAD, Calif., Jan.
SAN DIEGO, Dec. 17, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
- Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, Dec.
IMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months SAN FRANCISCO and RARITAN, N.J.,
Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
- The word or words serving to define another word or expression, as in a dictionary entry.